Clinical Trials - June 8, 2015
ALK Partner Testing Allergy Drug
ALK’s partner MSD has produced encouraging results from a North American Phase III clinical trial of ALK’s investigational sublingual allergy immunotherapy tablet for the treatment of house dust mite allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favor of HDM SLIT-tablet compared with placebo, according to BioSpace.com. The primary endpoint […]